David S. Ege - Feb 3, 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role
Executive Vice President and Chief Technology Officer
Signature
/s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege
Stock symbol
MCRB
Transactions as of
Feb 3, 2023
Transactions value $
$0
Form type
4
Date filed
2/7/2023, 04:50 PM
Previous filing
Oct 31, 2022
Next filing
May 1, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MCRB Restricted Stock Units Award $0 +47.5K $0.00 47.5K Feb 3, 2023 Common Stock 47.5K Direct F1, F2
transaction MCRB Stock Option (Right to Buy) Award $0 +95K $0.00 95K Feb 3, 2023 Common Stock 95K $5.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter.
F3 The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

Executive Vice President and Chief Technology Officer